Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multicenter study of apatinib plus EGFR-TKI in EGFR-mutant advanced non-small cell lung cancer with slow progression after first-generation EGFR-TKI and known T790M status
ChiCTR-OPC-17013162Phase 4Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: progression-free survival. Started Nov 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OPC-17013162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17013162.